Syros Pharmaceuticals Inc (NASDAQ:SYRS) dropped 3.1% during trading on Wednesday . The company traded as low as $11.52 and last traded at $11.87, with a volume of 58,339 shares traded. The stock had previously closed at $12.25.

SYRS has been the subject of a number of research analyst reports. HC Wainwright initiated coverage on shares of Syros Pharmaceuticals in a research report on Monday, July 18th. They issued a “neutral” rating and a $10.00 target price for the company. Piper Jaffray Cos. initiated coverage on shares of Syros Pharmaceuticals in a research report on Monday, July 25th. They set an “overweight” rating and a $20.00 price objective for the company. Wedbush initiated coverage on shares of Syros Pharmaceuticals in a research report on Monday, July 25th. They set an “outperform” rating and a $18.00 price objective for the company. JMP Securities initiated coverage on shares of Syros Pharmaceuticals in a research report on Monday, July 25th. They set an “outperform” rating and a $22.00 price objective for the company. Finally, Cowen and Company initiated coverage on shares of Syros Pharmaceuticals in a research report on Monday, July 25th. They set an “outperform” rating for the company. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Syros Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of $17.50.

The stock’s 50 day moving average price is $0.00 and its 200 day moving average price is $0.00. The firm’s market capitalization is $272.54 million.

In other news, major shareholder Redmile Group, Llc bought 432,746 shares of the firm’s stock in a transaction that occurred on Wednesday, July 6th. The stock was bought at an average price of $12.50 per share, with a total value of $5,409,325.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Robert Nelsen bought 400,000 shares of the firm’s stock in a transaction that occurred on Wednesday, July 6th. The shares were purchased at an average cost of $12.50 per share, with a total value of $5,000,000.00. The disclosure for this purchase can be found here.

Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on developing treatments for cancer and immune-mediated diseases. The Company’s gene control platform focuses on identifying gene control targets linked to genomically defined patient populations, and drugging gene control targets.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.